Showing 7451-7460 of 8649 results for "".
- Results Published From 2-year Multicenter Study Illustrate Efficacy and Safety of Preserflo MicroShunthttps://modernod.com/news/results-published-from-2-year-multicenter-study-illustrate-efficacy-and-safety-of-preserflo-microshunt/2480287/Santen EMEA has announced the results from a 2-year multicenter study of the Preserflo MicroShunt in patients with primary open-angle glaucoma (POAG). The study showed that mean IOP was significantly reduced from 21.7±3.4 mmHg at baseline to 14.1±3.2 mmHg at year 2 (&
- Voptica Introduces Inverted Meniscus IOL to Improve Peripheral Vision at ESCRShttps://modernod.com/news/voptica-introduces-inverted-meniscus-iol-to-improve-peripheral-vision-at-escrs/2480285/Voptica SL has introduced what it is calling the first and only inverted meniscus intraocular lens (ArtIOLs) to improve peripheral vision, according to a company news release. Introduced at the 2021 ESCRS symposium in Amsterdam, ArtIOLs mimic the optics of the natural cry
- Comorbid Ophthalmic, Systemic Conditions Linked With Higher Risk of Dementiahttps://modernod.com/news/comorbid-ophthalmic-systemic-conditions-linked-with-higher-risk-of-dementia/2480281/People with both ophthalmic and systemic conditions were found to be at higher risk of dementia compared with those with only 1 such condition, according to a report in the American Journal of Managed Care. Some ophthalmic condition
- Novartis to Present New Data Highlighting Recent Safety-Specific Beovu Studies at EURETINA 2021https://modernod.com/news/novartis-to-present-new-data-highlighting-recent-safety-specific-beovu-studies-at-euretina-2021/2479502/At the upcoming EURETINA 2021 Virtual Congress, Novartis will present new data highlighting safety-specific Beovu studies, including: The Safety-Specific, Next-Generation Optical Coherence Tomography Analysis from HAWK: Preliminary Qualitative OCT Findings Associated with I
- Pixium Vision Expands Collaboration with Stanford University On Next Generation Prima System Implantshttps://modernod.com/news/pixium-vision-expands-collaboration-with-stanford-university-on-next-generation-prima-system-implants/2479492/Pixium Vision SA announced the expansion of a collaboration with academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD). “We are very excited to be extending our collaboration with
- Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congresshttps://modernod.com/news/oxurion-to-present-clinical-and-preclinical-data-at-upcoming-euretina-2021-virtual-congress/2479493/Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking p
- EyeGate Pharma Completes Target Enrollment in Phase 2 Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammationhttps://modernod.com/news/eyegate-pharma-completes-target-enrollment-in-phase-2-study-to-evaluate-pp-001-for-the-treatment-of-ocular-surface-inflammation/2479490/EyeGate Pharmaceuticals announced that it has completed target enrollment of 21 patients in the phase 2 proof-of-concept (POC) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001
- Horizon Therapeutics Initiates Phase 4 Clinical Trial Evaluating Tepezza for the Treatment of Chronic Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-initiates-phase-4-clinical-trial-evaluating-tepezza-for-the-treatment-of-chronic-thyroid-eye-disease/2479489/Horizon Therapeutics announced that the first patient has been enrolled in a phase 4 clinical trial evaluating the efficacy and safety of Tepezza for the treatment of chronic (inactive) Thyroid Eye Disease (TED). Tepezza is the first and only medicine approved by the FDA for the treatment of TED—
- Maxwell Hosts Recipients of Opening Your Eyes: The Vision Council Scholarship Fundhttps://modernod.com/news/maxwell-hosts-recipients-of-opening-your-eyes-the-vision-council-scholarship-fund/2479480/Last week, three-time Grammy winner, and modern soul star, Maxwell, honored three recipients of the “Opening Your Eyes: The Vision Council Scholarship Fund” at the Times Square EDITION hotel. During the celebratory event, Maxwell, on behalf of The Vision Council, presented three of th
- Visus Therapeutics to Host Its First Capital Markets Day Tomorrowhttps://modernod.com/news/visus-therapeutics-to-host-its-first-capital-markets-day-tomorrow/2479476/Visus Therapeutics will host its first Capital Markets Day for investors, analysts, and media tomorrow, August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue at 45th Street in New York City. During the Capital Markets Day, Ben Bergo, co-founder and chief executive